My Rehovot ( ISSN 1817-101X )

Apolitical journal on every aspect of life in Rehovot, Israel

Home | Archive | Rehovot.org | BizDir | rBB | rForum | Rentals | Property | Jobs | Makolet | Flowers | Car for Sale | TV | Photo Albums | Arts | Events | Obituaries/Guest Books | Sport | Bulletin Board (Rus) | Dating (Rus) | Advertise | Contacts
_ _Press go button to proceed with your subscription request          This is a link to MyRehovot.Info in Russian  This is a link to MyRehovot.Info in Hebrew  This is a link to MyRehovot.Info home in English
Visit Google Scholar, new search of quality scholar literature by Google   _

Fresh'n'tasty bread at Rehovot's authentic Brand New Berad house. Come in today for a degustation or a cup of coffee

Saturday, August 23, 2008

Beijing Olympics 2008: Michael Phelps is a Sonic Doper, Washington Post Science Writer Says, Quotes Based in Rehovot Scientific Doping Journal

or Listening to an iPod Is Like Taking Drugs

by Rick Weiss
Senior Fellow, Center for American Progress
Former Washington Post Science Reporter

Imagine you have qualified for the Olympics and are walking down a Beijing street the day before your event, when a vendor gives you a covert signal to come closer. You approach warily as he opens a flap of his trench coat, revealing something half tucked into an inside pocket.

“Pssst,” he says. “You want to win gold? Guaranteed to help. And perfectly legal.”

“What is it?” you ask, as he shows you a mysterious device, smaller than a credit card and with wires dangling from it.

“Intracranial transducers,’” he says in practiced English, pointing to the ends of the wires. “Stick them in your ears and they focus the brain, increase blood oxygen, prepare muscles for action. Made here in China.”

“So it’s a doping device!” you say with disgust.

“No, no,” the man exclaims in a hoarse whisper, looking around to make sure no one else has heard your incriminating comment. “Like I said, totally legal.”

“So what is it called?” you ask.

He looks askance again, then leans over and whispers in your ear: “‘iPod,’” he says. “We call it ‘iPod.’ It worked for Phelps. It can work for you.”

***

It is now a widely known fact that Michael Phelps, winner of a record-breaking eight gold medals in this year’s Olympics, is an iPod fanatic. In the minutes before diving into the pool, those trademark white wires were almost invariably hanging from his ears. He has confessed at various times to using tunes by Eminem, Young Jeezy, Lil’ Wayne and Jay-Z to motivate him and enhance his concentration.

When broken down to its mechanical elements, an iPod is nothing more, and nothing less, than what my hypothetical Chinese huckster was pitching—a device that transduces electrical energy into acoustical energy, namely music.


You see where I am going with this. And before I go any further, why don’t you get it out of your system? Let me have it. I know what’s coming because soon after I began to wonder about the parallels between iPoding and doping, an Israel-based medical doctor and scientist with whom I have communicated occasionally in the past—Alexei Koudinov, who among other things edits an online scientific publication called The Doping Journal—sent me a blog in which he raised the same issue. And that blog, I saw, had led to instant and effusive derision by his online readers.

“Who pays this guy to think up things like this?” one respondent wrote, after Koudinov argued the undoubtedly extreme case that Phelps should give up his medals. Others called the idea that music should be classified as a performance enhancer “asinine,” “silliness,” “a crock,” “ridiculous,” and “mean-spirited.”

One clever commentator claimed that “The writer of the article is qualified
to write for that [Doping] Journal: He is a Dope!” Another, less clever, called Koudinov’s posting “a waste of ink.” In fact, as with most online postings, no ink was involved.

But let’s pursue the idea a bit further. When broken down to its mechanical elements, an iPod is nothing more, and nothing less, than what my hypothetical Chinese huckster was pitching—a device that transduces electrical energy into acoustical energy, namely music. And as everyone knows, music can have profound psychological and physiological effects. It can relax a listener. It can anger or enthrall. It can excavate deep emotions and energy.

If that is not specific enough, consider research published in the Journal of Nursing Research in 2003, which showed that hospitalized infants who had music played for them had significantly higher oxygen levels in their blood than other babies . Now consider that the 2008 World Anti-Doping Code of the World Anti-Doping Agency, in Article M1 under the category of “Prohibited Methods,” bans methods of “artificially enhancing the uptake, transport or delivery of oxygen….”

I suppose this raises the interesting legal and philosophical question of what is “artificial.” In the words of one especially cynical blogger: “As just about everyone knows, breathing increases blood oxygenation. Should this also be considered illegal?” I won’t go that far. But even if normal breathing is acceptable, what about the arguably less-natural activities known as deep breathing or stretching or limbering up?

Moreover, music can affect more than mere oxygen levels. Koudinov cites research by Stefan Koelsch of the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig, Germany, who has published research on biological responses to music. According to Koelsch, music can induce biochemical “relaxing effects.” Given all the talk during this year’s Olympics about the risks and downsides of “having the jitters,” which can throw even the best of gymnasts off their balance beams, relaxation is clearly a big potential benefit.

Yet anti-jitter drugs, such as beta blockers, are expressly prohibited in many Olympic sports (including marksmanship, as evidenced last week when the North Korean Olympic shooter Kim Jong Su was stripped of his silver and bronze medals after blood tests came up positive for propranolol, which can slow a heart that is racing from nervousness and, in so doing, reduce anxiety and enhance concentration).

Phelps may even have received a double benefit by yanking out his ear buds in the last minute or two before competing. Research published in 2005 suggests that intense music followed by a sudden silent pause may be just the ticket for someone poised at the edge of an Olympic pool, since the music itself can boost arousal and the sudden silence that follows can induce, in handy sequence, a wave of relaxation.

“Music, especially in trained subjects, may first concentrate attention during faster rhythms, then induce relaxation during pauses,” that study concluded.

...continue reading full article at the ScienceProgress.org web site

Source: Rick Weiss. Is Michael Phelps A Sonic Doper? (Listening to an iPod Is Like Taking Drugs) Bioethics: Science Progress by AmericanProgress.org Published online 22 August 2008 [FullText]

Labels: ,

Saturday, July 26, 2008

Cancer Diagnostic Test by Rehovot's Rosetta's MicroRNA Technology Approved in US

Rosetta Genomics Ltd, Israel and Jersey City, NJ, reports its molecular test based on proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program.

CUMC is finalizing the commercial aspects of the test and will announce its clinical availability to patients nationwide after details are finalized later this year.

"This is a landmark event for us, marking the first step in the transformation of Rosetta Genomics into a commercial diagnostics company," said Amir Avniel, the company’s president and CEO. "Our proprietary microRNA platform technologies, which this test is based on, have enabled Columbia University Medical Center's high complexity molecular pathology laboratory to develop a highly sensitive and specific test, which is a key for optimal administration of targeted therapies for this devastating cancer.”

The test, performed on a sample of a patient's tumor, classifies squamous-cell carcinoma of the lung with sensitivity of 96% and specificity of 90%. The test uses microRNAs' sensitivity and specificity as biomarkers, which may offer a standardized and objective method for lung cancer classification.

"We value our partnership with Columbia University Medical Center and we look forward to continuing this collaboration," noted Ronen Tamir, the company’s chief commercial officer. "At the same time, once we complete the previously announced acquisition of Parkway Clinical Laboratories Inc in Pennsylvania, we plan to complement CUMC's commercial efforts by submitting the same type of test, developed and validated by Rosetta, for regulatory approval in the fourth quarter of 2008."

The advent of targeted, lung-cancer therapies directed at specific cellular alterations demands the most accurate classification possible for non-small cell lung carcinomas (NSCLC). A recently approved angiogenesis inhibitor (bevacizumab(1)) for NSCLC has been shown to be less effective against squamous-cell lung cancer. The targeted therapy includes a black-box warning about substantially higher rates of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC, which has led squamous-cell histology to be regarded by many as an exclusion criterion for the drug. Several other targeted drugs for NSCLC currently under development may require this type of sensitive differentiation.

Some 185,000 people annually are diagnosed with non-small cell lung cancer nationwide, and an estimated 60,000 patients annually are potential candidates for targeted therapy with bevacizumab in the United States.

Data presented in peer-reviewed publications has shown that two blinded-expert observers, when asked to give an independent histological classification of NSCLC, agreed only 74.7% of the time.

The company expects two additional tests based on its microRNA technology to be validated and submitted for regulatory approval during the second half of 2008 by labs in the United States. One test is designed to differentiate mesothelioma, an asbestos-associated cancer that develops in the pleura, from adenocarcinomas that either arise in the lung or spread to the lung and pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary.

MicroRNAs are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide a way to treat a wide range of human diseases. MicroRNAs have been shown to have different expression in various pathological conditions, and these differences may provide for a novel diagnostic strategy for many diseases.

The company's integrative research platform combining bioinformatics and lab processes has led to the discovery of hundreds of biologically validated, novel human microRNAs. Building on its IP position and proprietary platform technologies, Rosetta is working on applying these technologies in the development of a range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and women's health indications.

The first test based on the company's technology, differentiating squamous from non squamous non-small cell lung cancer, is approved through CUMC's high complexity molecular pathology lab, and the company expects two additional microRNA diagnostic tests with its technology will be validated and submitted for regulatory approval by licensed clinical labs in the United States in 2008.

Labels:

Monday, May 12, 2008

Anti-bacterial material developer Rehovot's Sure Inter. raises $5m

"Anti-bacterial material developer Sure raises $5m. Wanaka Capital Partners and C. Mer Industries invested in the company.

Anti-bacterial material developer Sure International Ltd. has raised $5 million from Wanaka Capital Partners and C. Mer Industries Ltd. (TASE: CMER). The Rehovot-based company products target the healthcare, food, environmental, and industrial markets.
Sure's anti-bacterial and anti-fungal materials can be integrated into plastics, preventing the reproduction of bacteria and fungi spores. The company was founded by Dr. Uriel (Uri) Halavee and Dr. Shmuel Bukshpan..."

Source: Gali Weinreb. Anti-bacterial material developer Sure raises $5m. Globes.co.il (7 May 08) [FullText]

Labels: , ,

Thursday, May 08, 2008

New program by Rehovot academic institute teaches science and math teachers

A new program at the Weizmann Institute in Rehovot is aimed at raising the low level of Israeli high-school pupils knowledge of scientific subjects and math that has been exposed in recent years in international comparison studies.

The innovative "Caesarea Program" will soon be inaugurated at the Rehovot institute. Made possible by the Caesarea Edmond Benjamin de Rothschild Foundation, it will offer masters' degrees in science education to outstanding high-school and middle-school science and math teachers. The three-year curriculum, prepared by Weizmann faculty members, will include studies designed to broaden and deepen scientific knowledge, meetings with scientists working at the cutting edge of research and practice in applying innovative approaches to teaching. Participants will also conduct research in the field of science teaching and gain first-hand experience in leading original initiatives.

Teachers will study two days a week for the first two years and one day a week in the third year. The rest of the week, the participants can continue their normal teaching duties. Participants will be selected on the basis of recommendations and personal interviews, and each will receive a study grant in addition to an exemption from tuition.

For teachers who already have advanced degrees, the program offers a multi-track option that will integrate practical studies with research. Participants in this branch of the program are also eligible for study scholarships. A continuing education program will be offered to those who finish either track, in collaboration with the science teaching department and other scientific departments at Weizmann, and with the Davidson Institute of Science Education, which also conducts its activities there. The continuing program will support participants in developing and implementing innovative science education projects.

The Caesarea Program is open to outstanding science and math teachers who have at least three years of experience. Those teachers chosen to participate are required to commit themselves to teaching for at least another three years. Interested candidates can write to Miriam Carmeli at miriam.carmeli[at]weizmann.ac.il.

Source: Judy Siegel Itzkovich. New Worlds: New program teaches science and math teachers. Health and SciTech. JPost.com (3 May 2008) [FullText]

Labels: , ,

Thursday, May 01, 2008

Rehovot scientists, activists debate if genetically modified foods are panacea or plague

The debate on genetically engineered crops could delay progress in addressing the global shortage of staple foods, Prof. Gad Galili of the Weizmann Institute of Science in Rehovot said Wednesday.

"Distribution of new, genetically engineered crops can help solve world hunger, but the question is where they are used," said Prof. Ayal Kimhi, head of teaching at the Hebrew University's Department of Agricultural Economics.

"If they're used in the US and Europe to increase production and send surpluses to poor countries, it will not solve the problem in poor countries, because farmers there would not be able to make a living" faced with competition from the cheaper imports, Kimhi said. "I think something positive that will come out of this crisis is an understanding that we need to change the agricultural policies in the West."

At a lecture at the Weizmann Institute in Rehovot, Galili, of the Department of Plant Sciences, spoke of the benefits and hazards of genetically modified organisms.

"Between a quarter and half a million children in developing children go blind every year as a result of vitamin A deficiency, and many of them die," he said.

The United Nations resolved in 2002 to end vitamin A deficiency, but despite the distribution of vitamin supplements there had not been much progress, Galili said.

"The question is, can we solve this using genetic engineering?" he said, pointing to a photo of a grain of rice.

The outer shell of rice grains produces vitamin A, but the inside, consumed as conventional white rice, does not, Galili said.

"The tradition in developing countries is to process rice grains in a way that it loses its shell," he said. "And since these are countries where pride is very important, the only way is to try and create vitamin A on the inside of rice grains as well."

According to Galili, this cannot be done by regular breeding, but only via genetic engineering.

By transferring six different genes from the shell to the core, scientists have created vitamin A-rich golden rice. Adults only need 300 grams of golden rice to satisfy their daily vitamin A requirement, Galili said.

Genetically modified organisms can also be more resistant to disease, pesticides, drought and temperature fluctuations, as well as higher in protein, vitamins, minerals and amino acids, Galili said.

But the golden rice and some other genetically modified organisms have yet to be tested or enter the market because of the controversy and public concern that surround the issue.

"There are ethical reasons, that God is the creator of new life forms; health issues, concerning long-term effects; ecological concerns - what would happen if GMO breed with other plants? And a lot of commercial concerns, that someone will find a way to profit off from this," Galili said.

Although scientists do not know the long-term effects of genetically modified organisms consumption, Galili said they were safer than conventionally interbred ones because scientists had full control over all the variables in the gene transfer.

As for the risk of contamination, Galili said, "If you put a virus into GMO, it will spread. But we safeguard it, there are expert committees that approve GMO, and one thing is certain: If someone wanted to insert a virus genome, or there was a contamination risk, it would not be approved."

Source: Gal Tziperman Lotan. Scientists, activists debate if genetically modified foods are panacea or plague. JPost.com (30 April 2008) [FullText]

Labels: , , ,

Saturday, April 12, 2008

The Weizmann Institute Science Festival: Smart Fun for the Whole Family

Where: The Weizmann Institute Science, Rehovot, Herzl Street, 5 min walk from Rehovot Train Station

When: April 23-24, 2008

This year’s Garoon Family Science Festival at the Weizmann Institute will be bigger and better than ever. Adults and children alike can experience the thrill of scientific discovery through a wide variety of exhibits, competitions, performances, workshops, tours, lectures and interactive demonstrations geared to every age group.

Among the activities to choose from: interactive workshops on everything from acrobatics to thinking games and “scientific” ice cream; talks on the science of films and techniques of film animation; panel discussions with scientists; lectures on current science topics; as well as the chance to learn how to extract DNA from lettuce or build a rocket. A special exhibit will show art created by children for the “Draw Me a Scientist” contest.

This year’s Science Festival will also feature an assortment of musical performances and workshops including “Journey from Beach to Drum,” with Chen Cymbalista and the Ashkelon Chamber Orchestra, as well as Gypsy-Balkan music, wandering Brazilian performances combining dance, movement and rhythm, a show featuring new musical instruments and a workshop in constructing musical instruments from recycled materials and junk.

This year’s contests, which require advance registration, are the “flying egg,” and a team treasure hunt. For more information and contest registration: 08-934-3959.

The festival will take place April 23-24 from 10:30 to 18:00. Information will be available to the public through the festival switchboard: 08-934-6090.

Journalists (only) who would like more information can call the Weizmann Institute Publications and Media Relations Department: Malka Barkan: 08-934-3856 or Tamar Gilboa: 08-934-3851, 054-263-8877.

Source: Weizmann Institute Media Department

Labels: , ,

Wednesday, March 26, 2008

Rehovot scientists succeed in designing artificial enzymes that also undergo “evolution in a test tube”

BIRTH OF AN ENZYME

Mankind triumphed in a recent “competition” against nature when scientists succeeded in creating a new type of enzyme for a reaction for which no naturally occurring enzyme has evolved. This achievement opens the door to the development of a variety of potential applications in medicine and industry.

Enzymes are, without a doubt, a valuable model for understanding the intricate works of nature. These molecular machines – which without them, life would not exist – are responsible for initiating chemical reactions within the body. Millions of years of natural selection have fine-tuned the activity of such enzymes, allowing chemical reactions to take place millions of times faster. In order to create artificial enzymes, a comprehensive understanding of the structure of natural enzymes, their mode of action, as well as advanced protein engineering techniques is needed. A team of scientists from the University of Washington, Seattle, and the Weizmann Institute of Science, Israel, made a crucial breakthrough toward this endeavor. Their findings have recently been published in the scientific journal Nature.

Enzymes are biological catalysts that are made from a string of amino acids, which fold into specific three-dimensional protein structures. The scientists’ aim was to create an enzyme for a specific chemical reaction whereby a proton (a positively charged hydrogen atom) is removed from carbon – a highly demanding reaction and rate-determining step in numerous processes for which no enzymes currently exist, but which would be beneficial in helping to speed up the reaction. During the first heat of the “competition,” the research team designed the “heart” of the enzymatic machine – the active site – where the chemical reactions take place.

The second heat of the competition was to design the backbone of the enzyme, i.e., to determine the sequence of the 200 amino acids that make up the structure of the protein. This was no easy feat seeing as there is an infinite number of ways to arrange 20 different types of amino acids into strings of 200. But in practice, only a limited number of possibilities are available as the sequence of amino acids determines the structure of the enzyme, which in turn, determines its specific activity. Prof. David Baker of the University of Washington, Seattle, used novel computational methodologies to scan tens of thousands of sequence possibilities, identifying about 60 computationally designed enzymes that had the potential to carry out the intended activity. Of these 60 sequences tested, eight advanced to the next “round” having showed biological activity. Of these remaining eight, three sequences got through to the “final stage,” which proved to be the most active. Drs. Orly Dym and Shira Albeck of the Weizmann Institute’s Structural Biology Department solved the structure of one of the final contestants, and confirmed that the enzymes created were almost identical to the predicted computational design.

But the efficiency of the new enzymes could not compare to that of naturally-occurring enzymes that have evolved over millions of years. This is where “mankind” was on the verge of losing the competition to nature, until Prof. Dan Tawfik and research student Olga Khersonsky of the Weizmann Institute’s Biological Chemistry Department stepped in, whereby they developed a method allowing the synthetic enzymes to undergo “evolution in a test tube” that mimics natural evolution. Their method is based on repeated rounds of random mutations followed by scanning the mutant enzymes to find the ones who showed the most improvement in efficiency. These enzymes then underwent further rounds of mutation and screening. Results show that it takes only seven rounds of evolution in a test tube to improve the enzymes’ efficiency 200-fold compared with the efficiency of the computer-designed template, resulting in a million-fold increase in reaction rates compared with those that take place in the absence of an enzyme.

The scientists found that the mutations occurring in the area surrounding the enzyme’s active site caused minor structural changes, which in turn, resulted in an increased chemical reaction rate. These mutations therefore seem to correct shortcomings in the computational design, by shedding light on what might be lacking in the original designs. Other mutations increased the flexibility of the enzymes, which helped to increase the speed of substrate release from the active site.

“Reproducing the breathtaking performances of natural enzymes is a daunting task, but the combination of computational design and molecular in vitro evolution opens up new horizons in the creation of synthetic enzymes,” says Tawfik. “Thanks to this research, we have gained a better understanding of the structure of enzymes as well as their mode of action. This, in turn, will allow us to design and create enzymes that nature itself had not ‘thought’ of, which could be used in various processes, such as neutralizing poisons, developing medicines, as well as for many further potential applications.”

Prof. Dan Tawfik's research is supported by the J & R Center for Scientific Research; the Jack Wolgin Prize for Scientific Excellence; Mr. and Mrs. Yossie Hollander, Israel; Mr. Rowland Schaefer, New York, NY; and the estate of Fannie Sherr, New York, NY. Prof. Tawfik is the incumbent of the Elaine Blond Career Development Chair.

Source: Weizmann Institute Media and Publications Department

Labels: ,

Friday, March 14, 2008

Olmert praises scientists for 'coming home', has nothing to offer except of corrupted university system

Original title: Olmert praises scientists for 'coming home'

Prime Minister Ehud Olmert met at Rehovot's Weizmann Institute of Science on Tuesday with four young scientists who returned to Israel after living abroad for years because of the lack of opportunities for teaching and research here.

"The larger the institute gets, the more scientists will join so it can advance excellence in Israeli society for all of us," Olmert said.

He was received on campus by institute president Prof. Daniel Zajfman, who presented four outstanding young scientists among 16 who returned to Israel and joined the Weizmann Institute faculty during the past year.

The four were Dr. Avishai Gal-Yam (an astronomer); Dr. Nirit Davidovich (a physicist); Dr. Michal Sharon (a biochemist); and Dr. Roni Paz (a brain researcher).

Olmert described the Weizmann Institute as a "pearl in the crown of Israeli society."

He later met with youths who are neither studying in high school nor working full time, but are part of a work-study project initiated by Dr. Ovad Kerem of the Davidson Institute for Science Education of the Weizmann Institute.

Source: Judy Siegel Itzkovich. Olmert praises scientists for 'coming home' JPost.com (11 March 2008) [FullText]

Labels: , ,

Monday, March 03, 2008

Robert H. Smith 'Feeding the Future' with $15 Million Gift to Rehovot Branch of the Hebrew University of Jerusalem

The Robert H. Smith Family Foundation has pledged a $15 million challenge grant to transform The Hebrew University of Jerusalem's Faculty of Agricultural, Food and Environmental Quality Sciences in Rehovot, Israel. The gift will be the cornerstone of the university's and American Friends of Hebrew University's "Feeding the Future through Sustainable Agriculture" campaign, a $51 million reorganization and expansion plan will broaden and accelerate Hebrew University's cutting-edge interdisciplinary research in plant and animal sciences, biochemistry, nutrition and environmental studies. New buildings, state-of-the-art laboratories and greenhouses will foster collaborative work between four academic Institutes addressing major challenges, among these: hunger and malnutrition, natural resource scarcity and the impact of global warming.

In recognition of the Foundation's generosity, the Faculty will be renamed "The Robert H. Smith Faculty of Agricultural, Food and Environmental Quality Sciences." American Friends of The Hebrew University (AFHU) is launching a $15 million fundraising campaign, seeking support from other American philanthropists and foundations.

"Thanks to the friendship and generosity of the Smith Family, The Hebrew University will expand its vital work in the field of agriculture," said George Schieren, president of AFHU. "Through this new challenge grant, Hebrew University will be able to establish two research institutes and propel agricultural research to new levels."

Robert H. Smith of Washington, DC, a visionary philanthropist, is a successful real estate developer who spearheaded the creation of Crystal City, Virginia. Mr. Smith and his family have been involved with Hebrew University and AFHU for decades. A former chairman of Hebrew University's International Board of Governors, he also served as president of the Washington DC chapter of AFHU.

The Faculty of Agriculture, including the Robert H. Smith Institute for Plant Sciences, is a worldwide leader in sustainable agriculture and environmental conservation. Innovations include: drip irrigation techniques adopted worldwide, plant-derived treatments for malaria, aquaculture and genetically enhanced produce and flowers.

"Hebrew University has led the development of technologies and techniques benefiting all semi-arid regions, and students from 155 countries have taken that knowledge home with them," said Peter Willner, AFHU's national executive director.

About The Hebrew University of Jerusalem

The Hebrew University of Jerusalem, located on three campuses in Jerusalem and a fourth in Rehovot, is one of the world's leading academic and research institutions. Faculty and alumni of The Hebrew University have won six Nobel Prizes in the past five years.

The University has consistently been ranked among the top 100 academic and research institutions worldwide in independent surveys, including Newsweek magazine.

The American Friends of The Hebrew University

American Friends of The Hebrew University (AFHU) is a national, not-for- profit organization which conducts fund raising activities in support of The Hebrew of Jerusalem.

AFHU CONTACT: David Kaiyalethe Joyce Grossman Dukas Public Relations jgrossman@afhu.org david@dukaspr.com 212.607.8540 212/704-7385 ext 119

The American Friends of The Hebrew University

Source: PRNewswire (4 March 2008) [FullText]

Labels: ,

Tuesday, February 26, 2008

Foundation Gives $15 million to HUJI Rehovot's Agricultural Branch

Smith Foundation gives Hebrew U. $15 million

The Robert H. Smith Family Foundation pledged $15 million to The Hebrew University of Jerusalem for promoting sustainable agriculture.

The grant, which will go to the univeristy's Faculty of Agricultural, Food and Environmental Quality Sciences in Rehovot, is part of a $51 million "Feeding the Future through Sustainable Agriculture” campaign to put the school at the forefront of research into sustainable agriculture.

The money will fund a reorganization and expansion of Hebrew Univeristy's interdisciplinary research in plant and animal sciences, biochemistry, nutrition and environmental studies, the school said in a release.

The project includes new buildings, state-of-the-art laboratories and greenhouses and more collaborative work between four academic institutions addressing major challenges such as hunger and malnutrition, natural resource scarcity and the impact of global warming.

The faculty for the program will be called “The Robert H. Smith Faculty of Agricultural, Food and Environmental Quality Sciences.”

Source: JTA, 22 Feb 2008

Labels: ,

Tuesday, January 08, 2008

Rehovot's Yosef Yarden Became the Member of the Israel Academy of Sciences and Humanities

Israeli basketball players are significantly smaller than their European counterparts, and so are their red mullets - the fish, that is. University of Haifa researchers, along with Italian colleagues discovered that red mullets off the coast of Israel are about five centimeters shorter than those in Italian waters. The adult male Israeli fish is an average of 146.3 millimeters long, while females are 176 millimeters. The Italians are 195 mm. (males) and 218 mm (females).

Prof. Ehud Spanier and Oren Sunin of the university's limnological institute say very young red mullets are longer, but this difference disappears with age; when fully grown Israeli red mullets are, on average, five centimeters shorter than Italian ones.

The reason, said the researchers, is nutrition. In the eastern end of the Mediterranean, there are sharp variations in the amount of food, while near Italy the supply is much more stable. When there isn't enough to eat, the mullets develop at a different pace. They have a growth spurt, and when they reach adolescence and can multiply, they compensate for the lack of food and grow more slowly. The young European fish, however, can take their time, reaching adolescence more slowly before producing offspring. Thus they are able to end up five cenimters longer than their Israeli cousins.

Mullets are a family (Mugilidae) of ray-finned fish found worldwide in coastal temperate and tropical waters, and in some species in fresh water also. Mullets have served as an important food source in Mediterranean Europe since Roman times. The family includes about 80 species.

It seems as if European fish, like European people, know how to enjoy the good life and good meals (and perhaps a sip of good wine at lunch?). But stressed Israeli life under constant pressure forces them to eat on the run.

THREE JOIN ACADEMY OF SCIENCES

Three scientists have joined the Israel Academy of Sciences and Humanities, the government's official adviser on science matters. At a ceremony at the academy in Jerusalem, the three joined the other 93 current members and delivered lectures on their field of interest. Fifty-three of the academy members are in the natural sciences and the rest in social sciences and humanities.

The new ones, appointed in a general meeting of the academy after nomination by members in the two divisions, are Prof. Ya'acov (Gerald) Blidstein of the department of Jewish thought at Ben-Gurion University of the Negev; Prof. Chava Turniansky of the Hebrew University of Jerusalem's Yiddish department; and Prof. Yosef Yarden of the biological control department of the Weizmann Institute in Rehovot.

Blidstein, renowned worldwide for his work on halacha and aggada, is the author of six books and scores of articles. He has also done extensive research on Maimonides.

Turniansky, an emeritus professor, has studied the history of Yiddish culture during the pre-modern era, and received the Bialik Prize for Jewish Thought.

Yarden is a research leader in the biological roles of hormone-like molecules called growth factors and their involvement in cancer. He is dean of the Weizmann school for master's degree studies, and chairman of the National Biotechnology Council.

ABRAMSKY TO HEAD R&D COUNCIL

Prof. Oded Abramsky, a senior neurologist and researcher at Hadassah University Medical Center in Jerusalem's Ein Kerem, has been appointed chairman of the National Council for Civilian Research and Development by President Shimon Peres. The nomination has already been approved by the cabinet, as requested by Science, Culture and Sport Minister Ghaleb Majadlah, and by Israel Academy of Sciences president Prof. Menachem Ya'ari.

The national council, established in 2004, serves as the government's adviser for planning and organizing civilian R&D; recommends general national policy in this field to the government on an annual basis; recommends national priorities in civilian R&D; makes suggestions on infrastructure projects in science and technology; and advises the government and ministerial committee on science and technology and the forum of government chief scientists on matters connected to government R&D.

Abramsky, 67, headed Hadassah's neurology department for 17 years and also chaired Hadassah's Agnes Ginges Center for Human Neurogenetics. Among his many positions, he also served as dean of the Hebrew University-Hadassah School of Medicine, chief scientist of the Health Ministry and chairman of the board of governors of the U.S.-Israel Binational Science Foundation. A retired colonel in the Israel Defense Forces, Abramsky served as assistant head of research and development for the IDF and the Defense Ministry. A prolific researcher and writer, he has published four books and over 300 articles. He is also is a fellow of the Royal College of Physicians of the United Kingdom, and a member of the Institute of Medicine of the American National Academy of Sciences.

CLIMATE CHANGING FASHION

You take an umbrella when rain is forecast. But actual change in climate will have a profound effect on clothes and fashion, changing styles, fabrics and laundering, according to a University of Maryland expert. "Remember Jimmy Carter's sweaters from the 1970s energy crisis? With Seventh Avenue proclaiming that 'green is the new black,' we can expect a surge in fashion innovations in response to climate change," says Jo Paoletti, an American studies professor at the University of Maryland, and an expert in apparel design and the history of textile and clothing.

"As the impact of global warming is felt, we can anticipate debates over cotton versus polyester, and increasing concern about the water and energy needed to launder clothing," adds Paoletti, who has spent over 25 years researching and writing about clothing in America. "In the future, smart clothing that monitors and adjusts to body temperature may help reduce our need for air conditioning and heating."

Climate change could also affect the frequency of buying new clothes, and the size of our wardrobes.

Source: Judy Siegel-Itzkovich. What our fish and our basketball players have in common. JPost.com (22 December 2007) [FullText]

Labels: ,

Sunday, December 16, 2007

Rehovot scientists move to defuse Huntington's time bomb

Huntington's disease is a genetic time bomb: This horrific disorder appears at a predictable age in adulthood, causing a progressive decline in mental and neurological function, and finally death. So far, there is no cure for Huntington's or a number of similar ailments collectively known as trinucleotide repeat diseases. They are caused by an unusual genetic mutation: A three-letter piece of genetic code is repeated over and over in one gene. Scientists at the Weizmann Institute in Rehovot have now proposed a mechanism that provides an explanation for the remarkable precision of the time bomb. This explanation may point researchers in the direction of a possible prevention or cure.

The number of repeats in Huntington's patients ranges between 40 to over 70. Scientists have noted that, like clockwork, one can predict - by how many times the sequence repeats in a patient's gene - both the age at which the disease will appear and how quickly it will progress. The basic assumption has been that the protein fragment containing the amino acid (glutamine) encoded in the repeating triplet slowly builds up in the cells until it reaches toxic levels. This theory, unfortunately, fails to explain some of the clinical data. For instance, it doesn't explain why patients with two copies of the Huntington's gene don't exhibit symptoms earlier than those with a single copy. Plus, glutamine is produced in only some trinucleotide diseases, whereas the correlation between sequence length and onset age follows the same general curve in all of them, implying a common mechanism not tied to glutamine.

Research student Shai Kaplan in Prof. Ehud Shapiro's lab in the institute's biological chemistry department and the computer sciences and applied mathematics department realized the answer might lie in somatic mutations - changes in the number of DNA repeats that build up in our cells. The longer the sequence, the greater the chance of additional mutation, and the scientists realized that the genes carrying the disease code might be accumulating more and more DNA repeats, until some critical threshold is crossed.

Based on the literature on some 20 known trinucleotide repeat diseases and their knowledge of the mechanisms governing somatic mutation, Shapiro, Kaplan (also in the molecular cell biology department), and Dr. Shalev Itzkovitz created a computer simulation that could take a given number of genetic repeats and show both the age of onset and the way in which the disease would progress. Their findings were recently presented in PLoS Computational Biology.

The new disease model appears to fit all the facts and to provide a good explanation for the onset and progression of all the known trinucleotide repeat diseases. Lab experiments could test this model, say the scientists and, as it predicts that all these diseases operate by somatic expansion of a trinucleotide repeat, it also suggests that a cure for all might be found in a drug or treatment that slows the expansion process.

Source: Judy Siegel-Itzkovich. Weizmann scientists move to defuse Huntington's time bomb. JPost.com (15 December 2007) [FullText]

Labels:

Sunday, September 02, 2007

Rehovot Researchers Discover Survival Mechanism for Blood Cancer Cells

Chronic Lymphocytic Leukemia is a type of blood cancer in which specific white blood cells, called B lymphocytes or B cells, build up in the blood, bone marrow and lymph nodes.

The lifespan of a normal B cell is limited by an internal self-destruct program but, in cancer cells, this mechanism breaks down. B cells that don't self-destruct can live on to multiply and accumulate in dangerous amounts.

A team of scientists headed by Professor Idit Shachar of the Weizmann Institute's Immunology Department and Dr. Michal Haran of the Hematology Institute of the Kaplan Medical Center recently discovered what makes these cancer cells stay alive.

They then launched a targeted attack on the survival mechanism they discovered and succeeded to significantly raise cancer cell mortality rates. Their findings may lead to future treatments for this disease, as well as for other diseases in which B lymphocytes accumulate in the blood.

In previous research, Shachar had found that a specific receptor — a protein on the outer surface of healthy B cells — fulfills a crucial role in helping these cells to survive. She wondered if the same protein might also be a central player in the abnormally high survival rates of cancerous B cells.

Members of Shachar's research team, including Inbal Binsky, Diana Starlets, Yael Gore and Frida Lantner, together with Kaplan Medical Center doctors Haran, Lev Shvidel, Professor Alan Berrebi and Nurit Harpaz, scientists from Yale University and David Goldenberg of the Garden State Cancer Center in New Jersey, examined B cells taken from chronic lymphocytic leukemia patients.

They discovered that, even in the earliest stages of the disease, these cells have an unusually high level of both the survival receptor and another protein that binds to the receptor.

The scientists found that this protein, in binding to the receptor, initiates a series of events within the cell that leads to enhanced cell survival capabilities. For instance, in one of these events, a substance is produced that helps to regulate the cells' lifespan. This substance causes another protein to be produced, which then prevents the self-destruct program from being activated. The team treated the chronic lymphocytic leukemia cells with an antibody that attached to the survival receptor, blocking its activity and causing the cancer cell death rate to soar.

The antibodies they used are produced by the firm Immunomedics, in New Jersey, and are currently entering clinical trials for the treatment of several different types of cancer. Following this research, which has revealed the mechanism for the antibody's actions, the company is planning trials for chronic lymphocytic leukemia, as well.

Shachar said, "The abnormally elevated levels of this receptor seem to be important factors in the development of this disease, right from the beginning, and they are responsible for the longevity of these cancerous B cells. Blocking the receptor or other stages in the pathway they activate might be a winning tactic, in the future, in the war against cancers involving B cells."

Source: Weizmann discovers survival mechanism for blood cancer cells. www.Sun-Sentinel.com (30 August 2007) [FullText]

Labels: , ,

Monday, May 14, 2007

Rehovot Scientist Among the Winners of this year's Wolf Prizes

The chemistry prize will be jointly awarded to Prof. Ada Yonath (born 1939 in Israel) of the Weizmann Institute of Science and Rehovot, and Prof. George Feher (born 1924 in Czechoslovakia) of the University of California, San Diego for ingenious structural discoveries of the ribosomal machinery of peptide-bond formation and the light-driven primary processes in photosynthesis...

Source: Judy Siegel. Two Israeli academics among the winners of this year's Wolf Prizes. Jerusalem Post (13 May 2007) [FullText]


Labels:

Home | Archive | Rehovot.org | BizDir | rBB | rForum | Rentals | Property | Jobs | Makolet | Flowers | Car4sale | TV | Photo Albums | Arts | Events | Obituaries/Guest Books | Sport | Bulletin Board (Rus) | Dating (Rus) | Advertise | Contacts
_ _Press go button to proceed with your subscription request          This is a link to MyRehovot.Info in Russian  This is a link to MyRehovot.Info in Hebrew  This is a link to MyRehovot.Info home in English
Visit Google Scholar, new search of quality scholar literature by Google   _